Galena Biopharma Inc (NASDAQ:GALE) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Monday. The firm currently has a $0.75 price objective on the biotechnology company’s stock. Zacks Investment Research’s target price suggests a potential upside of 19.39% from the stock’s current price.
According to Zacks, “Galena Biopharma, Inc. is a biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. Galena Biopharma, Inc., formally known as RXi Pharmaceuticals Corporation, is based in Portland, Oregon. “
Other equities research analysts also recently issued reports about the company. Maxim Group raised their price target on Galena Biopharma from $1.00 to $4.00 and gave the stock a “buy” rating in a research note on Friday, December 2nd. FBR & Co downgraded Galena Biopharma from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $11.00 to $4.00 in a research note on Monday, February 6th. Four equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $2.93.
This article was originally published by and is the sole property of Zolmax. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://zolmax.com/investing/zacks-investment-research-upgrades-galena-biopharma-inc-gale-to-strong-buy/1248556.html
Shares of Galena Biopharma (NASDAQ:GALE) traded up 0.4638% during trading on Monday, hitting $0.6282. The company’s stock had a trading volume of 2,821,941 shares. Galena Biopharma has a 1-year low of $0.53 and a 1-year high of $49.80. The firm’s 50 day moving average is $0.86 and its 200-day moving average is $1.21. The company’s market capitalization is $6.82 million.
var userip;Your IP Address: document.write(userip);
In other news, major shareholder Hudson Bay Capital Management sold 2,363,441 shares of the stock in a transaction dated Wednesday, February 8th. The stock was sold at an average price of $0.84, for a total transaction of $1,985,290.44. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 2.02% of the company’s stock.
Galena Biopharma Company Profile
Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galena Biopharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.